Children with devastating muscle-wasting conditions may retain more motor function when treatment begins early, offering hope for families facing this progressive genetic disease. Real-world evidence from 46 pediatric patients demonstrates that nusinersen, the first approved therapy for spinal muscular atrophy, can meaningfully alter disease trajectories when administered promptly.
The Turkish cohort study tracked patients across all three main SMA types over median treatment periods ranging from 15 to 42 months. Most striking were motor function improvements: severe Type 1 patients increased median neuromuscular scores from 23 to 41 points, while three previously immobile children achieved supported walking. Type 2 patients doubled their functional motor scores from 4 to 8 points, and Type 3 patients maintained or improved mobility despite disease progression expectations. However, three Type 3 patients lost independent walking ability, highlighting variable individual responses.
The critical finding involves treatment timing: earlier intervention correlated significantly with better motor outcomes across all disease severities. This supports emerging clinical consensus that nusinersen works best when muscle deterioration is minimal, reinforcing arguments for newborn screening programs.
These outcomes represent meaningful progress for a condition historically considered uniformly fatal or severely disabling. Yet limitations remain apparent—the therapy requires repeated spinal injections, costs exceed $100,000 annually, and benefits vary considerably between patients. The study's retrospective design and single-center origin also constrain broader applicability. Still, for families navigating SMA diagnoses, this evidence suggests that prompt treatment access could preserve motor abilities that traditional supportive care cannot maintain, fundamentally shifting quality-of-life expectations for affected children.